Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 2/20 | 0.40 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 11/20 | 0.39 |
| ▸ | PPARG | P37231 | 10/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15284771 | 1.00 | ITGA4 (0.40) | ITGA4ITGB7PPARAPPARGPPARD | |
| SCHEMBL16561823 | 0.79 | ITGA4 (0.38) | ITGA4ITGB7PPARAPPARGPPARD | |
| SCHEMBL18534192 | 0.79 | ITGA4 (0.38) | ITGA4ITGB7PPARAPPARGPPARD | |
| SCHEMBL882678 | 0.77 | MDM4 (0.42) | PPARAPPARGPPARDACECTSK | |
| SCHEMBL15284890 | 0.77 | MDM4 (0.42) | PPARAPPARGPPARDACECTSK | |
| SCHEMBL17925378 | 0.71 | ITGB3 (0.43) | ITGA4ITGB7PPARAPPARGPPARD | |
| SCHEMBL1111037 | 0.70 | ACE (0.55) | ITGA4ITGB7PPARAPPARGPPARD | |
| SCHEMBL1111041 | 0.70 | ACE (0.55) | ITGA4ITGB7PPARAPPARGPPARD | |
| SCHEMBL17925379 | 0.70 | GSTP1 (0.36) | ITGA4ITGB7CTSKCTSSALDH1A1 | |
| SCHEMBL16561830 | 0.70 | GSTP1 (0.36) | ITGA4ITGB7CTSKCTSSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765154-B2 | Phosphohistidine analogs | THE ROCKEFELLER UNIVERSITY (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765154-B2 | Phosphohistidine analogs | THE ROCKEFELLER UNIVERSITY (US) | 2017-09-19 | — | — | US | disclosed |
| US-20150344589-A1 | PHOSPHOHISTIDINE ANALOGS | THE ROCKEFELLER UNIVERSITY (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344589-A1 | PHOSPHOHISTIDINE ANALOGS | THE ROCKEFELLER UNIVERSITY (US) | 2015-12-03 | — | — | US | disclosed |
| US-9035068-B2 | Phosphohistidine analogs | THE ROCKEFELLER UNIVERSITY (US) | 2015-05-19 | — | — | US | disclosed |
| US-9035068-B2 | Phosphohistidine analogs | THE ROCKEFELLER UNIVERSITY (US) | 2015-05-19 | — | — | US | disclosed |
| US-20130260398-A1 | PHOSPHOHISTIDINE ANALOGS | THE ROCKEFELLER UNIVERSITY (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130260398-A1 | PHOSPHOHISTIDINE ANALOGS | THE ROCKEFELLER UNIVERSITY (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2012040523-A2 | PHOSPHOHISTIDINE ANALOGS | THE ROCKEFELLER UNIVERSITY (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130260398-A1 | PHOSPHOHISTIDINE ANALOGS | PHPT1, PTMS, CHAMP1 | ITGA4 2529/4885ITGB7 2207/4885PPARA 4287/4885 |
| US-20150344589-A1 | PHOSPHOHISTIDINE ANALOGS | PHPT1, PTMS, CHAMP1 | ITGA4 2553/4885ITGB7 2470/4885PPARA 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.